What does this research mean for the field?

A novel contactless overnight monitoring device using machine learning can detect COPD exacerbations up to five days prior to treatment with 72% sensitivity and 98% specificity. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the diagnostic accuracy of the DistaSense™ device for early detection of COPD exacerbations.

May 20, 2026

B102-18 Diagnostic Accuracy of a Novel Contactless Monitoring Device for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Detection

Key Points

To evaluate the diagnostic accuracy of the DistaSense™ device for early detection of COPD exacerbations.
Monitored 49 individuals with COPD overnight using DistaSense device for heart rate and respiratory rate detection.
Developed a predictive model using machine learning incorporating motion, restlessness, and respiratory waveform analysis.
Defined exacerbation as the need for oral antibiotics and/or corticosteroids.
Detected 32 exacerbations among 14 patients over 2547 nights of monitoring.
Achieved 72% sensitivity and 98% specificity in detecting exacerbations.
Negative predictive value of 99% and positive predictive value of 40%.

Abstract

Abstract Introduction/Rationale COPD exacerbations have a substantial impact on patients’ health and quality of life, with associated socio-economic burden.1 Home monitoring to facilitate earlier detection of exacerbations has demonstrated promising results in reducing the number of emergency visits and hospitalisations. However, the evidence supporting widespread adoption is inconclusive.2 Further development is required to explore the utility of signals measured within a person’s home in providing early, accurate, and objective diagnosis of COPD exacerbation. Method We evaluated the diagnostic accuracy of the DistaSense™ device, which provides overnight non-contact monitoring of heart rate (HR) and respiratory rate (RR) to facilitate early detection of COPD exacerbations. Patients were monitored every night, overnight and an exacerbation was defined as the need for oral antibiotics and/or corticosteroids. A predictive model using machine learning was developed to identify exacerbations, which includes analysis of motion, restlessness, and respiratory waveform. Result 49 people with COPD (55% male, mean (SD) age 70.1(6.8) years, mean (SD) FEV1 57.1(19) % predicted) were monitored. 32 exacerbations among 14 patients were detected, with a total of 2547 nights of monitoring. HR and RR signals were integrated into 326 features. The predictive model demonstrated that DistaSense™ was able to detect an exacerbation five days before the start of treatment, achieving a sensitivity of 72% for a specificity of 98%. The negative predictive value was 99% and the positive predictive value was 40%. Conclusion In the largest study of its kind reported to date, the DistaSense™ device offers exciting potential features for early diagnosis of COPD exacerbations five days prior to treatment. A high specificity was achieved, supporting the development of this remote home monitoring system to facilitate early diagnosis of COPD exacerbations. This abstract is funded by: LDT (Life Detection Technologies) and LPDP (Indonesian Endowment Fund for Education Agency)

Bookmark

Cite This Study

Syam et al. (Fri,) studied this question.

synapsesocial.com/papers/6a0d4fbff03e14405aa9b244 https://doi.org/https://doi.org/10.1093/ajrccm/aamag162.1916

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark